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Clinical PerspectiveWhat Is New?Coenzyme Q10 supplementation ameliorated statin‐associated muscle symptoms, such as muscle pain, muscle weakness, muscle cramps, and muscle tiredness, demonstrated by the present meta‐analysis.What Are the Clinical Implications?Coenzyme Q10 supplementation provided a complementary approach to statin‐associated muscle symptoms, which would be significant for the patients with cardiovascular diseases who are intolerant to statin treatment because of statin‐associated muscle symptoms.

Introduction {#jah33514-sec-0008}
============

Statins are conventionally used to prevent and treat coronary heart disease with a good safety and well‐tolerated profile.[1](#jah33514-bib-0001){ref-type="ref"} However, statin‐induced myopathy, a main adverse effect of statins, is one of the primary reasons for statin discontinuation that contributes to adverse cardiovascular outcomes.[2](#jah33514-bib-0002){ref-type="ref"}

Statin‐induced myopathy covers a broader range of statin‐associated muscle symptoms (SAMSs) and is subdivided by the presence or absence of creatine kinase (CK) elevation.[3](#jah33514-bib-0003){ref-type="ref"} Previous studies[4](#jah33514-bib-0004){ref-type="ref"}, [5](#jah33514-bib-0005){ref-type="ref"}, [6](#jah33514-bib-0006){ref-type="ref"} have demonstrated a reduction in coenzyme Q10 (CoQ10) after statin treatment, which might be associated with statin‐induced myopathy. However, whether CoQ10 supplementation ameliorates statin‐induced myopathy remains controversial. Some studies[7](#jah33514-bib-0007){ref-type="ref"}, [8](#jah33514-bib-0008){ref-type="ref"}, [9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"} have indicated that CoQ10 supplementation ameliorated statin‐induced myopathy. In contrast, other studies[11](#jah33514-bib-0011){ref-type="ref"}, [12](#jah33514-bib-0012){ref-type="ref"}, [13](#jah33514-bib-0013){ref-type="ref"}, [14](#jah33514-bib-0014){ref-type="ref"}, [15](#jah33514-bib-0015){ref-type="ref"} have suggested that there is no beneficial effect of CoQ10 supplementation. A previous meta‐analysis, performed by Banach et al,[16](#jah33514-bib-0016){ref-type="ref"} failed to validate the benefit of CoQ10 supplementation on statin‐induced myopathy, which did not include the latest published randomized controlled trials (RCTs)[9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [14](#jah33514-bib-0014){ref-type="ref"}, [17](#jah33514-bib-0017){ref-type="ref"} of CoQ10 supplementation. Therefore, the present meta‐analysis of RCTs was designed to reassess whether CoQ10 supplementation ameliorates statin‐induced myopathy.

Methods {#jah33514-sec-0009}
=======

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because the present article is a systematic review and meta‐analysis; thus, the source data are available for consultation, reproduction, and analysis on web‐based medical libraries.

This study was performed according to the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta‐Analysis statement.[18](#jah33514-bib-0018){ref-type="ref"}

Data Source and Search Strategies {#jah33514-sec-0010}
---------------------------------

Two reviewers (H.Q. and M.G.) searched PubMed, EMBASE, and Cochrane Library with no language restrictions from inception to January 2018 to identify all existing literature. Medical subject headings terms and free‐text terms were used in each database with the following relevant keywords: "coenzyme Q10" and "statin" and "randomized controlled trials." A manual search was also performed to identify relevant references from the selected articles and published reviews. The studies were eligible if they met the following inclusion criteria: (1) randomized, controlled, parallel, or crossover trial; (2) the intervention group received statin plus CoQ10, and the comparison group received statin plus placebo; and (3) the outcome involved in the severity of muscle symptoms or plasma CK was available.

Data Extraction and Assessment of Study Quality {#jah33514-sec-0011}
-----------------------------------------------

Two reviewers (H.Q. and M.G.) extracted data independently. If a disagreement occurred between them, it was resolved by consulting with a third investigator (D.‐z.S.). We would contact the authors if the article was only published with abstracts, and the studies failing to obtain original data were excluded. The data were extracted from each individual eligible study as follows: (1) the first author\'s name and publication year; (2) intervention duration; (3) inclusion criteria; (4) patient number; (5) patients' age; (6) percentage of men; and (7) clinical outcomes. The methodological quality of eligible studies was determined according to the recommendation of the *Cochrane Handbook*.[19](#jah33514-bib-0019){ref-type="ref"}

Statistical Analysis {#jah33514-sec-0012}
--------------------

In this meta‐analysis, continuous data were used to analyze the weighted mean difference (WMD) with the effect size of the 95% confidence interval (CI). Heterogeneity in eligible studies was evaluated using the χ^2^ test on the basis of Cochran\'s Q test and I^2^ statistic at the *P*\<0.10 level of significance, and quantification of heterogeneity was calculated using the I^2^ metric, which describes the percentage of total variation estimated to be attributable to heterogeneity rather than chance. When *P* for the heterogeneity is \<0.1 and I^2^≥50%, the interstudy heterogeneity is considered to be statistically significant. The fixed‐effect model and random‐effect model were used in the meta‐analysis.[20](#jah33514-bib-0020){ref-type="ref"} We performed subgroup analysis and meta‐regression to detect the potential sources of heterogeneity in the condition of I^2^≥50%. Sensitivity analysis was performed to assess the robustness of the pooled WMDs by eliminating one study at a time. The meta‐regression, providing a linear regression using the random‐effects model, predicts the effect size from a predictor variable. Exp indicates the change in the average effect size associated with 1‐SD increase in the predictor, and the effect size of the 95% CI is presented. Adjusted *R* ^2^ explains the proportion of the predictor variable on between‐study variance. The publication bias was evaluated by funnel plot, Egger regression test, and the Begg‐Mazumdar correlation test. Statistical analysis was performed using Stata (version 12.0). There is no registered protocol for the present meta‐analysis.

Results {#jah33514-sec-0013}
=======

Description of Included Studies {#jah33514-sec-0014}
-------------------------------

A total of 868 studies (351 from PubMed, 404 from EMBASE, and 113 from the Cochrane Library) were identified; 231 articles were excluded as duplicated records. After the titles and abstracts of articles were screened, 586 were excluded because of review format, an improper study type, and/or improper comparisons. After the remaining 51 full‐text articles were reviewed, 39 were excluded because of improper comparisons, irrelevant outcomes, and/or unavailable outcomes. Finally, 12 articles[7](#jah33514-bib-0007){ref-type="ref"}, [8](#jah33514-bib-0008){ref-type="ref"}, [9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [12](#jah33514-bib-0012){ref-type="ref"}, [13](#jah33514-bib-0013){ref-type="ref"}, [14](#jah33514-bib-0014){ref-type="ref"}, [15](#jah33514-bib-0015){ref-type="ref"}, [17](#jah33514-bib-0017){ref-type="ref"}, [21](#jah33514-bib-0021){ref-type="ref"}, [22](#jah33514-bib-0022){ref-type="ref"} published in English from 2007 to 2017, with sample sizes ranging from 37 to 76 patients and intervention duration ranging from 30 days to 3 months, were entered into our meta‐analysis (Figure [1](#jah33514-fig-0001){ref-type="fig"}, [Table](#jah33514-tbl-0001){ref-type="table"}). The effect of CoQ10 supplementation on SAMSs was evaluated in 9 RCTs,[7](#jah33514-bib-0007){ref-type="ref"}, [8](#jah33514-bib-0008){ref-type="ref"}, [9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [12](#jah33514-bib-0012){ref-type="ref"}, [13](#jah33514-bib-0013){ref-type="ref"}, [14](#jah33514-bib-0014){ref-type="ref"}, [15](#jah33514-bib-0015){ref-type="ref"} and plasma CK was evaluated in 10 RCTs.[7](#jah33514-bib-0007){ref-type="ref"}, [8](#jah33514-bib-0008){ref-type="ref"}, [9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [12](#jah33514-bib-0012){ref-type="ref"}, [15](#jah33514-bib-0015){ref-type="ref"}, [17](#jah33514-bib-0017){ref-type="ref"}, [21](#jah33514-bib-0021){ref-type="ref"}, [22](#jah33514-bib-0022){ref-type="ref"} The total number of patients was 575 (294 in the CoQ10 supplementation group and 281 in the placebo group).

![Literature search process and study selection.](JAH3-7-e009835-g001){#jah33514-fig-0001}

###### 

Basic Characteristics of Patients

  Study                                                            Duration   Inclusion Criteria                                     Patients (T/P)   Age, y        Men, %        Outcome          
  ---------------------------------------------------------------- ---------- ------------------------------------------------------ ---------------- ------------- ------------- --------- ------ -------------------------------------------------------------------------------------------------------------------
  Caso et al, 2007[7](#jah33514-bib-0007){ref-type="ref"}          30 d       Dyslipidemia treated with statin and reporting MSs     32 (18/14)       58±3          64±2          66.6      35.7   Muscle pain (PSS, PIS), plasma CK concentrations
  Fedacko et al, 2013[8](#jah33514-bib-0008){ref-type="ref"}       3 mo       Patients treated with statin and reporting MSs         60 (34/26)       59.6±8.9      55.4±12.4     54.5      36.8   Muscle pain, muscle weakness, tiredness, muscle cramps (VAS score), plasma CK
  Skarlovnik et al, 2014[9](#jah33514-bib-0009){ref-type="ref"}    30 d       Patients treated with statin and reporting MSs         50 (25/25)       64.5±1.9      65.6±2.1      44        48     Muscle pain (PSS, PIS), plasma CK
  Tóth et al, 2017[10](#jah33514-bib-0010){ref-type="ref"}         3 mo       Dyslipidemia treated with statin                       70 (35/35)       58.4±13.8     61.96±12.2    51.4      48.6   Muscle pain, muscle weakness, muscle cramps, and muscle fatigue (subject questionnaire), plasma CK concentrations
  Taylor et al, 2015[11](#jah33514-bib-0011){ref-type="ref"}       8 wk       Dyslipidemia treated with statin and reporting MSs     38 (20/18)       58±10         60±10         N         N      Muscle pain (PSS, PIS), plasma CK concentrations
  Young et al, 2007[12](#jah33514-bib-0012){ref-type="ref"}        12 wk      Patients treated with simvastatin and reporting MSs    44 (22/22)       59±2          59±2          54.5      45.4   Myalgia score, plasma CK, plasma CoQ10 concentrations
  Bookstaver et al, 2012[13](#jah33514-bib-0013){ref-type="ref"}   3 mo       Patients treated with statin and reporting MSs         76 (40/36)       61.6          61.8          52.5      30.5   Muscle pain (VAS score)
  Rott et al, 2016[14](#jah33514-bib-0014){ref-type="ref"}         12 wk      Patients treated with statin and reporting MSs         37 (17/20)       61±18         57.4±11       64.7      70     Muscle pain (VAS score)
  Bogsrud et al, 2013[15](#jah33514-bib-0015){ref-type="ref"}      12 wk      Patients treated with atorvastatin and reporting MSs   41 (20/21)       58 (32, 73)   58 (32, 73)   42.8      45     Muscle pain (VAS score), plasma CK concentrations
  Pek et al, 2016[17](#jah33514-bib-0017){ref-type="ref"}          12 wk      Dyslipidemia treated with statin                       40 (20/20)       43.1±11.3     49.2±12.2     90        80     Plasma CK concentrations
  Mabuchi et al, 2007[21](#jah33514-bib-0021){ref-type="ref"}      12 wk      Dyslipidemia treated with atorvastatin                 49 (24/25)       61±8          60±8          25        32     Plasma CK concentrations
  Deichmann et al, 2013[22](#jah33514-bib-0022){ref-type="ref"}    6 wk       Athletes aged ≥50 years and taking statin              38 (19/19)       63.5±8.2      63.5±8.2      78.9      78.9   Plasma CK concentrations

CK indicates creatine kinase; CoQ10, coenzyme Q10; MS, muscle symptom; N, not mentioned; P, placebo group; PIS, pain interference score; PSS, pain severity score; T, CoQ10 supplementation group; VAS, visual analog scale.

Quality Assessment {#jah33514-sec-0015}
------------------

"Low risk," "high risk," or "unclear risk" was categorized for all of the included 12 studies, according to 7 risk biases presented in sequence generation, allocation sequence concealment, blinding of patients and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias (Figure [2](#jah33514-fig-0002){ref-type="fig"}). Taken together, no obvious attrition bias or reporting bias was observed, and the randomization and blinding in the included studies were considered adequate in the meta‐analysis, according to the *Cochrane Handbook*.[19](#jah33514-bib-0019){ref-type="ref"}

![Risk of bias summary.](JAH3-7-e009835-g002){#jah33514-fig-0002}

Meta‐Analysis {#jah33514-sec-0016}
-------------

Nine RCTs[7](#jah33514-bib-0007){ref-type="ref"}, [8](#jah33514-bib-0008){ref-type="ref"}, [9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [12](#jah33514-bib-0012){ref-type="ref"}, [13](#jah33514-bib-0013){ref-type="ref"}, [14](#jah33514-bib-0014){ref-type="ref"}, [15](#jah33514-bib-0015){ref-type="ref"} (222 patients in the CoQ10 supplementation group versus 211 patients in the placebo group) evaluated the effect of CoQ10 supplementation on SAMSs. Compared with the placebo, CoQ10 supplementation ameliorated muscle pain (WMD, −1.60; 95% CI, −1.75 to −1.44; *P*\<0.001), muscle weakness (WMD, −2.28; 95% CI, −2.79 to −1.77; *P*=0.006), muscle cramps (WMD, −1.78; 95% CI, −2.31 to −1.24; *P*\<0.001), and muscle tiredness (WMD, −1.75; 95% CI, −2.31 to −1.19; *P*\<0.001) from the results of the fixed‐effect model (Figure [3](#jah33514-fig-0003){ref-type="fig"}). To ensure the reliability of the outcome, the analysis using a randomized effect model was also performed, and the results showed that CoQ10 supplementation ameliorated muscle pain (WMD, −1.46; 95% CI, −2.16 to −0.76; *P*\<0.001) and muscle weakness (WMD, −2.54; 95% CI, −4.07 to −1.01; *P*=0.006) (Figure [4](#jah33514-fig-0004){ref-type="fig"}). A significant heterogeneity for the outcome of muscle pain was observed (I^2^=89.6%, *P*\<0.001) (Figures [3](#jah33514-fig-0003){ref-type="fig"} and [4](#jah33514-fig-0004){ref-type="fig"}), which had no obvious correlation with administration doses of CoQ10 (exp, 1.00; 95% CI, 0.99--1.01; adjusted *R* ^2^=−12.33%; *P*=0.79), CoQ10 supplementation time (exp, 1.04; 95% CI, 0.96--1.04; adjusted *R* ^2^=−23.96%; *P*=0.98), or year of publication (exp, 1.15; 95% CI, 0.85--1.55; adjusted *R* ^2^=2.57%; *P*=0.31) (Figure [5](#jah33514-fig-0005){ref-type="fig"}A through [5](#jah33514-fig-0005){ref-type="fig"}C).

![Forest plot for statin‐associated muscle symptoms: coenzyme Q10 vs placebo (fixed‐effect model). CI indicates confidence interval; ID, identification; WMD, weighted mean difference.](JAH3-7-e009835-g003){#jah33514-fig-0003}

![Forest plot for statin‐associated muscle symptoms: coenzyme Q10 vs placebo (random‐effect model). CI indicates confidence interval; ID, identification; WMD, weighted mean difference.](JAH3-7-e009835-g004){#jah33514-fig-0004}

![Meta‐regression plot. A, Mean change in muscle pain score according to administration doses of coenzyme Q10 (CoQ10). B, Mean change in muscle pain score according to CoQ10 supplementation time. C, Mean change in muscle pain score according to year of publication. D, Mean change in plasma creatine kinase (CK) according to administration doses of CoQ10. E, Mean change in plasma CK level according to CoQ10 supplementation time. F, Mean change in plasma CK level according to year of publication.](JAH3-7-e009835-g005){#jah33514-fig-0005}

Ten RCTs[7](#jah33514-bib-0007){ref-type="ref"}, [8](#jah33514-bib-0008){ref-type="ref"}, [9](#jah33514-bib-0009){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [12](#jah33514-bib-0012){ref-type="ref"}, [15](#jah33514-bib-0015){ref-type="ref"}, [17](#jah33514-bib-0017){ref-type="ref"}, [21](#jah33514-bib-0021){ref-type="ref"}, [22](#jah33514-bib-0022){ref-type="ref"} (237 patients in the CoQ10 supplementation group versus 225 patients in the placebo group) evaluated the effect of CoQ10 supplementation on plasma CK. Compared with placebo, CoQ10 supplementation did not decrease the plasma CK (WMD, 0.09; 95% CI, −0.06 to 0.24; *P*=0.23), according to the result from the fixed‐effect model (Figure [6](#jah33514-fig-0006){ref-type="fig"}), which was consistent with the result from the random‐effect model (WMD, 0.03; 95% CI, −0.40 to 0.46; *P*=0.85) (Figure [7](#jah33514-fig-0007){ref-type="fig"}). There was no difference among regions on the outcome (Figures [8](#jah33514-fig-0008){ref-type="fig"} and [9](#jah33514-fig-0009){ref-type="fig"}). A significant heterogeneity (I^2^=80.3%, *P*\<0.001) (Figures [6](#jah33514-fig-0006){ref-type="fig"} and [7](#jah33514-fig-0007){ref-type="fig"}) was observed in the included studies, which was independent of the administration doses of CoQ10 (exp, 0.99; 95% CI, 0.99--1.00; adjusted *R* ^2^=6.59%; *P*=0.45), CoQ10 supplementation time (exp, 0.99; 95% CI, 0.97--1.01; adjusted *R* ^2^=8.27%; *P*=0.30), and year of publication (exp, 0.95; 95% CI, 0.83--1.06; adjusted *R* ^2^=20.7%; *P*=0.24) (Figure [5](#jah33514-fig-0005){ref-type="fig"}D through [5](#jah33514-fig-0005){ref-type="fig"}F).

![Forest plot for plasma creatine kinase: coenzyme Q10 vs placebo (fixed‐effect model). CI indicates confidence interval; ID, identification; WMD, weighted mean difference.](JAH3-7-e009835-g006){#jah33514-fig-0006}

![Forest plot for plasma creatine kinase: coenzyme Q10 vs placebo (random‐effect model). CI indicates confidence interval; ID, identification; WMD, weighted mean difference.](JAH3-7-e009835-g007){#jah33514-fig-0007}

![Forest plot for plasma creatine kinase on the basis of region (fixed‐effect model). CI indicates confidence interval; ID, identification; WMD, weighted mean difference.](JAH3-7-e009835-g008){#jah33514-fig-0008}

![Forest plot for plasma creatine kinase on the basis of region (random‐effect model). CI indicates confidence interval; ID, identification; WMD, weighted mean difference.](JAH3-7-e009835-g009){#jah33514-fig-0009}

Sensitivity Analysis {#jah33514-sec-0017}
--------------------

To ensure the reliability of the present meta‐analysis, we performed sensitivity analysis to evaluate the robustness of the pooled WMDs by eliminating each study one at a time sequentially, which indicated that the heterogeneity among the studies did not change significantly for the effect of CoQ10 supplementation on SAMSs and on plasma CK.

Publication Bias {#jah33514-sec-0018}
----------------

Three methods, including funnel plot, Egger regression test, and the Begg‐Mazumdar correlation test, were used to evaluate publication bias for the effect of CoQ10 on SAMSs, and no obvious publication bias was found (Begg‐Mazumdar correlation test, Kendall\'s score=−8, continuity‐corrected z=−0.83, continuity‐corrected *P*=0.47; Egger regression test, coefficient, 0.29; 95% CI, −3.41 to 3.99; *P*=0.86) (Figure [10](#jah33514-fig-0010){ref-type="fig"}A through [10](#jah33514-fig-0010){ref-type="fig"}C). For the effect of CoQ10 on plasma CK, there was also no evidence of publication bias according to the results of a funnel plot, the Begg‐Mazumdar correlation test (Kendall\'s score=13, continuity‐corrected z=1.16, continuity‐corrected *P*=0.28), and the Egger regression test (coefficient, −0.25; 95% CI, −3.24 to 2.73; *P*=0.85) (Figure [10](#jah33514-fig-0010){ref-type="fig"}D through [10](#jah33514-fig-0010){ref-type="fig"}F).

![Publication bias. A, Funnel plot for muscle pain. B, Begg test for muscle pain. C, Egger test for muscle pain. D, Funnel plot for plasma creatine kinase (CK). E, Begg test for plasma CK. F, Egger test for plasma CK. WMD indicates weighted mean difference.](JAH3-7-e009835-g010){#jah33514-fig-0010}

Discussion {#jah33514-sec-0019}
==========

In the meta‐analysis performed by Banach et al,[16](#jah33514-bib-0016){ref-type="ref"} only 6 studies with 302 patients were included, and no beneficial effect of CoQ10 supplementation on statin‐induced myopathy was documented, which might be attributed to the limited number of enrolled studies and their small sample sizes. In the present meta‐analysis, 6 newly published RCT studies were included, and the effect of CoQ10 supplementation on statin‐induced myopathy in 12 RCTs with 575 patients was comprehensively evaluated. In contrast to the previous meta‐analysis, the present study demonstrated that CoQ10 supplementation ameliorated SAMSs, such as muscle pain, muscle weakness, muscle cramps, and muscle tiredness, independent of administration doses of CoQ10 (100--600 mg/d) or CoQ10 supplementation time (30 days to 3 months).

Lowering low‐density lipoprotein cholesterol with statin therapy reduces cardiovascular disease risk by up to 40% in a wide range of patients. However, a high prevalence of statin‐induced myopathy reported from studies adversely affects the cardiovascular disease benefits of statins.[23](#jah33514-bib-0023){ref-type="ref"} The present study demonstrated that CoQ10 supplementation ameliorated SAMSs, indicating that CoQ10 supplementation might be a therapeutic approach for statin‐induced myopathy. The mechanism of statin‐induced myopathy is not yet clear, but one possible mechanism is mitochondrial dysfunction resulting from a reduction in circulating/intramuscular CoQ10.[3](#jah33514-bib-0003){ref-type="ref"}, [4](#jah33514-bib-0004){ref-type="ref"} The RCT results[15](#jah33514-bib-0015){ref-type="ref"}, [17](#jah33514-bib-0017){ref-type="ref"}, [24](#jah33514-bib-0024){ref-type="ref"}, [25](#jah33514-bib-0025){ref-type="ref"}, [26](#jah33514-bib-0026){ref-type="ref"}, [27](#jah33514-bib-0027){ref-type="ref"}, [28](#jah33514-bib-0028){ref-type="ref"} demonstrated that statins reduced circulating CoQ10 by 16% to 54%; a meta‐analysis[6](#jah33514-bib-0006){ref-type="ref"} of 6 RCTs also suggested a significant reduction in plasma CoQ10 after statin treatment, regardless of the statin solution, treatment duration, or treatment dose. For changes in intramuscular CoQ10, Choi et al documented that statins decreased CoQ10 levels in cardiac muscle and skeletal muscle.[29](#jah33514-bib-0029){ref-type="ref"}, [30](#jah33514-bib-0030){ref-type="ref"} The studies performed by Liu et al revealed that the reduction of circulating/intramuscular CoQ10 after statin treatment decreased the phosphorylation potential of adenosine diphosphate and the activity of mitochondrial complex I and IV, which contributes to mitochondrial dysfunction.[31](#jah33514-bib-0031){ref-type="ref"}, [32](#jah33514-bib-0032){ref-type="ref"}, [33](#jah33514-bib-0033){ref-type="ref"}, [34](#jah33514-bib-0034){ref-type="ref"} Recently, polymorphisms in the coenzyme Q2 gene, important in the synthesis of CoQ10, were reportedly strongly associated with statin‐induced myopathy.[35](#jah33514-bib-0035){ref-type="ref"}, [36](#jah33514-bib-0036){ref-type="ref"} Therefore, a deficiency of CoQ10 may be involved in statin‐induced myopathy, and CoQ10 supplementation might be an approach to ameliorate statin‐induced myopathy.

Compared with placebo, CoQ10 supplementation did not decrease plasma CK regardless of the administration doses of CoQ10 and the duration of CoQ10 supplementation, which was consistent with previous clinical studies and a meta‐analysis[8](#jah33514-bib-0008){ref-type="ref"}, [10](#jah33514-bib-0010){ref-type="ref"}, [11](#jah33514-bib-0011){ref-type="ref"}, [16](#jah33514-bib-0016){ref-type="ref"}, [17](#jah33514-bib-0017){ref-type="ref"} because of certain reasons. First, no clear correlation between plasma CK and statin‐induced myopathy has yet been demonstrated, indicating that plasma CK would not be regarded as a sensitive marker for statin‐induced myopathy.[37](#jah33514-bib-0037){ref-type="ref"}, [38](#jah33514-bib-0038){ref-type="ref"} Second, the baseline plasma CK levels in the enrolled studies could not be extracted from the included studies, so whether CoQ10 supplementation had a beneficial effect on plasma CK in the patients with CK elevation could not be evaluated. Third, the plasma CK level generally increased after membrane damage of muscle cells, such as rhabdomyolysis. There was no reduction of plasma CK after CoQ10 supplementation, suggesting that the effect of CoQ10 on statin‐induced myopathy might be attributed to maintaining mitochondrial function rather than protecting the membrane of muscle cells.[3](#jah33514-bib-0003){ref-type="ref"}

There are several limitations in the present meta‐analysis. First, there were only few eligible RCTs, and most of them included relatively small populations; thus, the impact of the variables (eg, age, sex, and exercise) on the outcome could not be evaluated. Second, the eligible studies were heterogeneous because of the enrolled population characteristics and dose and duration of CoQ10 supplementation. However, we performed meta‐regression and sensitivity analysis to warrant the reliability of the present meta‐analysis.

Conclusion {#jah33514-sec-0020}
==========

CoQ10 supplementation ameliorated SAMSs, implying that CoQ10 supplementation might be a complementary approach to ameliorate statin‐induced myopathy.
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